#USA #Fremont #Alamar Biosciences #NULISAseq #pTau Assays

Alamar Biosciences Enhances NULISAseq™ CNS Disease Panel 120

Alamar Biosciences, a leader in precision proteomics aiming to enable the earliest disease detection, has recently announced the expansion of its NULISAseq™ CNS Disease Panel 120. This advanced panel now features cutting-edge assays for brain-derived phosphorylated Tau (pTau) proteins. The upgraded panel includes pTau217, pTau181, pTau231, and total Tau (tTau), which are measured directly from blood samples, offering unprecedented sensitivity and specificity for studying neurodegenerative diseases.

Importance of Phosphorylated Tau in Neurodegenerative Diseases

Phosphorylated Tau has emerged as a critical biomarker for the early detection and monitoring of Alzheimer’s disease and other tauopathies. The newly added features of the CNS Disease Panel 120 focus specifically on detecting brain-derived forms of pTau, overcoming limitations of existing assays that fail to differentiate between peripheral and central Tau species. This capability allows for the simultaneous measurement of two groups of pTau and tTau species—one specifically for brain-derived Tau species and the other combining Tau from brain and peripheral tissues.

Dr. Yuling Luo, CEO, founder, and chairman of Alamar Biosciences, emphasized the significance of this development: "Researchers have long sought a reliable blood-based solution to track Tau pathology in the brain. By integrating assays for pTau217, pTau181, pTau231, and total Tau into our NULISAseq CNS Disease Panel 120, we empower scientists to investigate the full spectrum of Tau pathology with exceptional sensitivity and throughput. This advancement will accelerate biomarker-driven research and drug development for Alzheimer’s disease and related neurodegenerative disorders."

Dr. Nicholas Ashton, Ph.D., director of neurodegenerative biomarker research at Banner Health, also noted the importance of being able to detect brain-derived pTau species directly from blood, stating, "This represents a critical step in the early detection and monitoring of Alzheimer’s disease and related conditions. Previously, we could not distinguish between intrinsic and peripheral pTau in a multiplex manner. Recent findings have underscored the necessity of detecting brain-derived pTau to attain higher specificity for Alzheimer's disease. Alamar’s new CNS panel presents an unprecedented opportunity to improve the diagnostic accuracy and clinical relevance of these biomarkers, significantly impacting patient care and clinical research."

Continuous Commitment to Neuroscience

Alamar Biosciences remains committed to collaboration with the neuroscience community to gain insights into biomarkers that facilitate earlier diagnoses, patient stratification, and therapy monitoring. This expansion of the NULISAseq CNS Disease Panel 120 reflects their ongoing dedication to supporting researchers and advancing the field of neurodegeneration.

For more information about the NULISAseq CNS Disease Panel 120 and Alamar Biosciences' portfolio of proteomics solutions, visit www.alamarbio.com.

Conclusion

As Alamar Biosciences pushes forward in the realm of precision proteomics, the enhancement of the NULISAseq™ CNS Disease Panel 120 showcases the potential for innovative approaches in the detection and understanding of neurodegenerative diseases, particularly Alzheimer's Disease. With significant advancements in biomarker sensitivity and specificity, the future of early detection and treatment monitoring in neurology looks brighter than ever.